S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DRNA stock logo

About Dicerna Pharmaceuticals (NASDAQ:DRNA) Stock

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DRNA Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
DRNA Jan 2022 22.500 call
DRNA Jul 2022 40.000 call(CONTR
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Dicerna Pharmaceuticals: Q3 Earnings Snapshot
See More Headlines


DRNA Company Calendar

Last Earnings
11/09/2021
Today
6/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRNA
Employees
302
Year Founded
N/A

Profitability

Net Income
$-112,750,000.00
Pretax Margin
-63.82%

Debt

Sales & Book Value

Annual Sales
$164.31 million
Book Value
$1.84 per share

Miscellaneous

Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80

Key Executives

  • Douglas M. FambroughDouglas M. Fambrough
    President, Chief Executive Officer & Director
  • James B. WeissmanJames B. Weissman
    Chief Operating Officer & Executive Vice President
  • Douglas W. Pagán
    Chief Financial Officer
  • Bob D. BrownBob D. Brown
    Chief Scientific Officer
  • Shreeram AradhyeShreeram Aradhye
    Chief Medical Officer & Executive Vice President













DRNA Stock - Frequently Asked Questions

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to the consensus estimate of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same quarter last year, the business posted ($0.29) earnings per share.

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $38.22.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals (NASDAQ:DRNA) has a market capitalization of $2.99 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112,750,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

The company employs 302 workers across the globe.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The official website for the company is www.dicerna.com. The biopharmaceutical company can be reached via phone at (617) 621-8097, via email at cerdman@macbiocom.com, or via fax at 617-612-6298.

This page (NASDAQ:DRNA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -